Global dPCR and qPCR Industry was valued at USD 3.8 Billion for the year 2018. dPCR and qPCR Industry is further expected to grow at a CAGR of 9.2% from 2018 to reach USD 6.85 Billion by the year 2025. European region holds the major Industry share whereas Asia Pacific region is considered as the fastest growing Industry in the forecasted period. It is observed that the developing countries from an emerging Asia Pacific Industry are anticipated to grow at a strongly in the next 5 years.
Global dPCR and qPCR Industry Share and Size by 2025 (USD Billion)
The main considerations that fuel the development of the Industry are increment in the rate of irresistible maladies alongside hereditary clutters all inclusive. What's more, expanding headways in PCR systems and research exercises that use PCR supplement the Industry development. Nonetheless, specialized inadequacies in the dPCR and qPCR, alongside staggering expenses of cutting edge PCR gadgets limit the development of the Digital PCR (dPCR) and ongoing PCR (qPCR) industry. Additionally, undiscovered locales and rising progress from plant-determined medications to genome-based medications will offer beneficial open doors for the Digital PCR (dPCR) and continuous PCR (qPCR) industry.
Polymerase chain response (PCR) mastery is utilized to heighten or make various duplicates of deoxyribonucleic acid (DNA) arrangement of intrigue. Polymerase chain response (PCR) skill is used in an assortment of uses going from DNA cloning, practical examination of qualities, paternity testing, discovery of infectious maladies, finding of innate sicknesses, and legal sciences. Quantitative PCR (qPCR) and digital PCR (dPCR) are two primary sorts of polymerase chain response (PCR) advances. Digital PCR is a similarly new strategy for DNA heightening and evaluation that uses sub-atomic checking convention. Digital PCR is primarily used to recognize articulation of alleles, track viral infection to an individual bacterial cell, measure disease qualities, and arrange fetal DNA in circling blood. The principle advantage of dPCR is that it is insensate to response viability, and does not require arrangement of standard bends. Constant PCR, likewise distinguished as quantitative PCR (qPCR), decides PCR enhancement simultaneously as the reaction continues. qPCR does not require post heightening preparing, which diminishes the turnaround time of the deliberate methodology and the danger of infection of enhanced DNA or RNA.
Major market Players in dPCR and qPCR Industry are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., BioMerieux S.A., Fluidigm Corporation, Takara Bio Inc., Bio-Rad Laboratories Inc., Affymetrix Inc., Qiagen N.V., Takara Bio Inc., RainDance Technologies Inc., Agilent Technologies, Inc., Danaher Corporation, Abbott Laboratories, Merck KGaA, Becton, and Dickinson Company. Similarly, various growth strategies adopted by Tier 1 & 2 players such as merger and acquisition has provided comprehensive Industry opportunities for a various stakeholder in the value chain.
SWOT Analysis of DPCR and qPCR Industry
Technology Development in PCR technology.
Successful Completion of the Human Genome Project
Technical limitation associated with qPCR and dPCR
Growing market in penetration in emerging countries
Implementation of MIQE guidelines for publishing qPCR and dPCR Industry
qPCR and Digital PCR Industry, By Technology
qPCR and Digital PCR Industry, By Product and Service
qPCR and Digital PCR Industry, By Application
qPCR and Digital PCR Industry, By End User
DPCR and qPCR Industry Overview, By Region
• Rest of Europe
• Rest of Asia-Pacific
• Latin America
• Middle East & Africa